- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03315741
The Safety and Tolerability of Pirfenidone for BOS After HCT (STOP-BOS)
The Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years at randomization
- Clinical symptoms (e.g., dyspnea or cough) consistent with BOS of ≥ 2 months duration
- Presence of cGVHD in an organ other than lung
Subjects must have had recent pulmonary function test (PFTs) measured for at least 3 months prior to study enrollment that show:
- A decrease in %FVC and/or %FEV1 ≥ 20% at Screening compared with pre-transplant baseline.
- Bronchodilator response on PFT testing that results in an FEV1 < 75%
Diagnosis of BOS by one of the following criteria:
- Transbronchial or surgical lung biopsy demonstrating the obliterative bronchiolitis lesion
- Volumetric CT scan with lung density analysis with ≥ 28% air trapping (1).
- NIH-based PFT criteria for the diagnosis of BOS: FEV1/FVC <0.7 and FEV1 < 75%
- Evidence of clinical improvement after treatment for BOS has been initiated.
- No features supporting an alternative diagnosis by transbronchial biopsy, bronchoalveolar lavage (BAL), surgical lung biopsy, culture and non-culture based data, if performed
- Adequate organ and marrow function including: liver function as defined by a total bilirubin below the upper limit of normal (ULN), excluding patients with Gilbert's syndrome; AST/SGOT or ALT/SGPT < 3 x ULN; alkaline phosphatase < 2.5 x ULN; renal function as defined by a CrCl > 30 mL/min, calculated using the Cockcroft-Gault formula; cardiac electrophysiologic stability as defined by an electrocardiogram (ECG) with a QTc interval < 500 msec at Screening; and bone marrow function as defined by a white blood cell count > 3 K/µL, an absolute neutrophil count > 15 K/µL and a platelet count > 20 K/µL
- Life expectancy > 6 months
- Participants must be able to understand and sign a written informed consent form and understand the importance of adherence to study treatment and protocol. In addition, participants must demonstrate a willingness to follow all study requirements, including the concomitant medication restrictions, throughout the study
Exclusion Criteria:
- Any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of pirfenidone e.g., presence of active GVHD of the gastrointestinal tract as manifested by rising liver function tests (LFTs) prior to initiation of study treatment
- Uncontrolled infection
- Major surgery within the past 2 months
- The use of another investigational drug within the previous 30 days.
- Inability to attend scheduled clinic visits
- Inability to perform pulmonary function testing
- Significant clinical change in health in the past 30 days
- Body mass index (BMI) < 17.5
- Life expectancy < 6 months due to any condition other than BOS that, in the opinion of the investigator, is likely to result in the death of the patient.
History of unstable or deteriorating cardiac or pulmonary disease (other than BOS) within the previous 6 months, including but not limited to the following:
- Unstable angina pectoris or myocardial infarction
- Congestive heart failure requiring hospitalization
- Uncontrolled clinically significant arrhythmias
- Pregnancy or lactation.
- Family or personal history of long QT syndrome
- Investigational therapy, defined as any drug that has not been approved for marketing for any indication in cGVHD will be restricted from the study
- The following medications may significantly increase the level of Pirfenidone and should not be taken concurrently including: fluvoxamine, ciprofloxacin > 500mg twice daily, systemically administered aminolevulinic acid, vemurafenib and enoxacin. Any other strong inhibitors of P450 isoenzymes CYP1A2, CYP2C9, 2C19, 2D6, and 2E1 should be avoided. Participants that cannot take alternative medications to those listed above will be excluded from this study.
Laboratory Exclusions
- Any of the following LFT criteria above specified limits: total bilirubin above the upper limit of normal (ULN), excluding patients with Gilbert's syndrome; aspartate or alanine aminotransferase (AST/SGOT or ALT/SGPT) >3 × ULN; alkaline phosphatase >2.5 × ULN
- Creatinine clearance (CrCl) <30 mL/min, calculated using the Cockcroft-Gault formula
- Electrocardiogram (ECG) with a QTc interval >500 msec at Screening
Medication Exclusions
1. Prior use of pirfenidone or known hypersensitivity to any of the components of study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Patient centered approach
Drug titration of maximum dose over 3-8 weeks
|
Tolerability of drug
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of participants that do not require a reduction in drug dose for more than 21 days due to adverse events.
Time Frame: 52 weeks
|
We will count the number of participants that do not require a reduction in drug dose of more than 21, non-continuous days due to adverse events.
Tolerability will be assessed during continuous treatment.
If the medication dosage increase results in the reoccurrence of a moderate adverse event or serious adverse event, lasting more than 21 days, then the event would be defined as "not tolerated".
If adverse events resolve before 21 days, then participants will attempt to again up-titrate the Pirfenidone dose, as tolerated.
If at least 25% of participants tolerate the drug, then investigators will deem that this study demonstrates adequate tolerability to proceed to a larger trial to examine drug efficacy.
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of participants that permanently discontinue drug due to adverse events.
Time Frame: 52 weeks
|
We will count the number of patients that permanently discontinue Pirfenidone due to adverse events.
A permanent discontinuation of drug is defined as discontinuation of the drug for more than 42 days.
|
52 weeks
|
The number of participants that temporarily discontinue drug due to adverse events.
Time Frame: 52 week
|
We will count the number of participants that temporarily discontinue Pirfenidone due to adverse events.
A temporary discontinuation of drug is defined as discontinuation of the drug for less than or equal to 42 days.
|
52 week
|
The number of patients that experience treatment-emergent adverse events
Time Frame: 56 week
|
Treatment emergent events are defined as those that start or worsen after the start of study treatment and up to 28 days after the last dose of study treatment.
AEs will be summarized by treatment group, system organ class, and preferred term, and also by the event's relationship to study treatment.
At each level of summation, patients will be counted only once, under the greatest severity and strongest study-drug relationship (as reported by the investigator).
|
56 week
|
The number of patients that experience treatment-emergent serious adverse events (SAEs)
Time Frame: 56 week
|
Serious adverse events (SAEs) are defined as those that result in: (i) death or are life threatening; (ii) result in hospitalization or prolong hospitalization; or (iii) result in disability (disruption of the participant's ability to conduct normal daily activities).
Serious adverse events will be summarized by treatment group, system organ class, and preferred term, and also by the event's relationship to study treatment.
At each level of summation, patients will be counted only once, under the greatest severity and strongest study-drug relationship (as reported by the investigator).
|
56 week
|
The number of patients that experience treatment-emergent deaths during the study period and for 28 days after the last dose of study treatment.
Time Frame: 56 week
|
Treatment emergent deaths are defined as those that occur after the start of study treatment and up to 28 days after the last dose of study treatment and are deemed by the investigator to be related to study treatment.
|
56 week
|
All-cause mortality
Time Frame: 56 week
|
We will count the total number of deaths during the study period and for 28 days after the last dose of study treatment
|
56 week
|
The number of patients that experience treatment-emergent changes in complete blood counts.
Time Frame: 52 week
|
The complete blood count measures the number white blood cells (WBCs) per liter (L) including differential counts of the type of WBCs, hemoglobin concentration (g/dL), and platelet count per liter.
|
52 week
|
The number of patients that experience treatment-emergent changes in liver function testing.
Time Frame: 52 week
|
We will assess treatment related changes in total bilirubin (mg/dL), AST/SGOT (units/L) or ALT/SGPT (units/L), alkaline phosphatase (units/L)
|
52 week
|
The number of patients that experience treatment-emergent changes in serum chemistries panel.
Time Frame: 52 week
|
We will assess treatment related changes in potassium (mEq/L), blood urea nitrogen (mg/dL) and serum creatinine (mg/dL).
|
52 week
|
The number of patients that experience treatment-emergent changes in the corrected QT-interval on electrocardiogram.
Time Frame: 52 week
|
We will evaluate changes in the interval from ventricular depolarization (Q-wave) to ventricular repolarization (T-wave) corrected for by heart rate
|
52 week
|
Body mass index
Time Frame: 52 week
|
We will measure changes in the participant's height (meters) and weight (kg) to determine changes in body mass index (kg/m^2)
|
52 week
|
Oxygen saturation
Time Frame: 52 week
|
We will measure the participant's oxygen saturation (%) at rest on room air.
|
52 week
|
Heart rate
Time Frame: 52 week
|
We will measure the participant's resting heart rate (beats per minute)
|
52 week
|
Chronic GVHD assessment
Time Frame: 56 week
|
Chronic GVHD symptoms will be assessed according to NIH cGVHD global severity score.
The global cGVHD severity score evaluates the severity of cGVHD in eight sites including the skin, mouth, eyes, gastrointestinal track, liver, lungs, joints and fascia, and genital track.
Each organ is assigned a severity score and composite scores are calculated based on the number of organs involved and the severity score within each affected organ.
|
56 week
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulmonary function testing: spirometric change from baseline to week 52.
Time Frame: 52 week
|
We will measure the participant's Forced Expiratory Volume in 1 second (FEV1: L, % predicted), and Forced Vital Capacity (FVC: L, % predicted)
|
52 week
|
Pulmonary function testing: diffusion capacity for carbon monoxide (DLCO) change from baseline to week 52.
Time Frame: 52 week
|
We will measure DLCO (ml/min/mmHg)
|
52 week
|
Change from Baseline to Week 52 in % air trapping as measured by volumetric CT thorax with lung density analysis
Time Frame: 52 week
|
We will use lung density analysis to radiographically quantify the percent air trapping between an inspiratory and expiratory CT scan.
|
52 week
|
BOS-related mortality
Time Frame: 52 week
|
We will count the number of participant deaths that are attributable to BOS.
|
52 week
|
Change from Baseline to Week 24 and 52 in dyspnea, as measured by the University of California at San Diego Shortness-of-Breath Questionnaire (UCSD SOBQ) score
Time Frame: 24 and 52 week
|
Changes in dyspnea, as measured by UCSD SOBQ score, from Baseline to Week 26 and 52 will be analyzed using the same methods described in Section 5.4.2.1. Baseline UCSD SOBQ score will be the average of the measurements recorded at the Screening and Day 1 visits. The UCSD SOBQ score will be repeated at Week 26 and 52. The magnitude of the treatment effect of pirfenidone will be presented as the distribution (number and percentage) of patients across two categories of change from Baseline:
|
24 and 52 week
|
Change from Baseline to Week 24 and 52 in Chronic GVHD (cGVHD) response
Time Frame: 24 and 52 week
|
The Lee cGVHD symptom scale contains 30 items in 7 subscales (skin, eye, mouth, lung, nutrition, energy and psychological), using a 5-point Likert scale.
Scores are linearly transformed to a 0-100 scale with higher values representing more severe symptoms.
A summary score also is calculated if 4 or more subscales are available for scoring.
Change in GVHD symptoms as measured by the Lee GVHD-symptom scale from Baseline to Week 26 and 52 will be evaluated.
|
24 and 52 week
|
Cumulative systemic corticosteroid exposure
Time Frame: 52 week
|
We will calculate the cumulative Prednisone dose (mg, or its corticosteroid equivalent) used by each participant over the trial period.
|
52 week
|
Use of other immunosuppressive medications
Time Frame: 52 week
|
We will calculate the type and the cumulative dose (mg) of other immune suppressive medications used by each participant over the trial period.
|
52 week
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joe L Hsu, MD, MPH, Stanford University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Bronchitis
- Bronchiolitis
- Bronchiolitis Obliterans
- Graft vs Host Disease
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Pirfenidone
Other Study ID Numbers
- IRB-43319
- VAR0158 (OTHER: OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiolitis Obliterans
-
University Hospital, Basel, SwitzerlandRecruitingBronchiolitis Obliterans Syndrome (BOS) | Bronchiolitis Obliterans (BO)Switzerland, Saudi Arabia
-
Washington University School of MedicineThe Foundation for Barnes-Jewish Hospital; Mallinckrodt; Centers for Medicare...Active, not recruitingBronchiolitis Obliterans Syndrome (BOS)United States
-
Renovion, Inc.RecruitingPre-Bronchiolitis Obliterans SyndromeUnited States
-
Children's Hospital Medical Center, CincinnatiRecruitingBronchiolitis Obliterans (BO) | Hematopoietic Stem Cell Transplant (HSCT)United States
-
Zambon SpATerminatedStem Cell Transplant Complications | GVHD, Chronic | Bronchiolitis Obliterans Syndrome (BOS)Spain, France, Germany
-
University of ChicagoCompletedBronchiolitis Obliterans SyndromeUnited States
-
University Hospital RegensburgClinAssess GmbHUnknownSteroid-refractory Bronchiolitis ObliteransGermany
-
KU LeuvenUniversity Hospital, Gasthuisberg; Fund for Scientific Research, Flanders,...CompletedGraft Rejection | Respiratory Infection | Bronchiolitis Obliterans Syndrome | Lymphocytic BronchiolitisBelgium
-
Hopital FochCompletedBronchiolitis Obliterans SyndromeFrance
-
Zambon SpAEnrolling by invitationBronchiolitis Obliterans | Bronchiolitis Obliterans Syndrome | Obliterative BronchiolitisFrance, United States, Spain, Israel, Belgium, Denmark, Germany, United Kingdom, Austria
Clinical Trials on Pirfenidone 267 MG [Esbriet]
-
Excalibur Pharmaceuticals, Inc.CompletedIdiopathic Pulmonary FibrosisUnited States
-
Hal ChapmanMassachusetts General Hospital; University of Michigan; University of Washington and other collaboratorsRecruitingIdiopathic Pulmonary FibrosisUnited States
-
Instituto de investigación e innovación biomédica...RecruitingSilicosis | Progressive Massive Fibrosis | Complicated SilicosisSpain
-
Blade TherapeuticsCompletedDrug Drug InteractionUnited States
-
University of MichiganGenentech, Inc.TerminatedChronic Lung Allograft Dysfunction | Disorder Related to Lung TransplantationUnited States
-
Jorge L PooCompletedCirrhosis, Liver | Liver Fibrosis | Chronic Liver Disease
-
University of California, San FranciscoGenentech, Inc.CompletedLung Transplant Rejection | Restrictive Chronic Lung Allograft DysfunctionUnited States
-
Pulmonary Research of Abingdon, LLCGenentech, Inc.CompletedCoal Workers' Pneumoconiosis (Complicated)United States
-
Hoffmann-La RocheCompletedIdiopathic Pulmonary FibrosisGreece
-
Manchester University NHS Foundation TrustHoffmann-La Roche; University of Liverpool; University of Manchester; National...Completed